Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Cisarua Mountain Dairy / Equity Capital Markets

<ul>
<li><strong>Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. </strong></li>
<li>Hong Kong IPO pipeline looks strong with Weilong Delicious Global, CANbridge Pharmaceuticals,  Asymchem Laboratories, and China Tourism Group either close to approval or seeking approval with HKEX soon.</li>
<li>Indonesia ECM is looking busier than ever this year with the launch of Cisarua Mountain Dairy (Cimory) and PT Avia Avian IPO bookbuilds this week.</li>
</ul>


Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. 
Hong Kong IPO pipeline looks strong with Weilong Delicious Global, CANbridge Pharmaceuticals,  Asymchem Laboratories, and China Tourism Group either close to approval or seeking approval with HKEX soon.
Indonesia ECM is looking busier than ever this year with the launch of Cisarua Mountain Dairy (Cimory) and PT Avia Avian IPO bookbuilds this week.


ECM Weekly (14th November 2021) - Cimory, Infervision, Daiwa House REIT, Weilong Delicious

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

CANbridge Pharmaceuticals / Equity Capital Markets

<p>Since June this year, there have been more and more topics about rare diseases in China. On June 30, Shaanxi Provincial Medical Insurance Bureau included 7 drugs for rare diseases such as Gaucher disease, Fabry disease and others into Shaanxi Provincial medical insurance coverage. On July 5, Jiangsu Province also added five rare diseases including Pompe disease, Spinal Muscular Atrophy and others to its medical insurance coverage. As rare diseases gradually attract government’s attention, related companies would also come into people’s vision. On June 30, <a href="https://www.smartkarma.com/entities/canbridge-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:33783:1" rel="noopener">CANbridge Pharmaceuticals (CAN HK)</a>, a leading China-based, global rare disease-focused biopharmaceutical company, submitted its prospectus to the HKEX. This insight mainly analyzed the industry characteristics, the commercialized products, the pipeline, and the concerns of the Company.</p>

Since June this year, there have been more and more topics about rare diseases in China. On June 30, Shaanxi Provincial Medical Insurance Bureau included 7 drugs for rare diseases such as Gaucher disease, Fabry disease and others into Shaanxi Provincial medical insurance coverage. On July 5, Jiangsu Province also added five rare diseases including Pompe disease, Spinal Muscular Atrophy and others to its medical insurance coverage. As rare diseases gradually attract government’s attention, related companies would also come into people’s vision. On June 30, CANbridge Pharmaceuticals (CAN HK), a leading China-based, global rare disease-focused biopharmaceutical company, submitted its prospectus to the HKEX. This insight mainly analyzed the industry characteristics, the commercialized products, the pipeline, and the concerns of the Company.

Pre-IPO CANbridge Pharmaceuticals - Insights on Products, Pipeline and the Concerns

China

CANbridge Pharmaceuticals is a global biopharmaceutical company dedicated to the research, development, and commercialization of transformative therapies for rare diseases and oncology. The company offers approved drugs such as Hunterase for Hunter syndrome and Livmarli for Alagille syndrome, and is developing a pipeline of gene therapies and other assets. It was founded in 2012 and is headquartered in Suzhou, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CANbridge Pharmaceuticals (1228 HK)

ECM Weekly (14th November 2021) - Cimory, Infervision, Daiwa House REIT, Weilong Delicious

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Sumeet Singh

Pre-IPO CANbridge Pharmaceuticals - Insights on Products, Pipeline and the Concerns

This article mainly analyzed CANbridge Pharmaceuticals in terms of its commercialized products, the pipeline, and the concerns, and the outlook of...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)